[{"orgOrder":0,"company":"Biorasi","sponsor":"Therapeutic Solutions","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"","productType":"Cell and Gene therapy","year":"2022","type":"Not Applicable","leadProduct":"Mesenchymal Stem Cells","moa":"Pro-inflammatory protein","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"Biorasi","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"Biorasi \/ Biorasi","highestDevelopmentStatusID":"10","companyTruncated":"Biorasi \/ Biorasi"},{"orgOrder":0,"company":"Biorasi","sponsor":"Citius Pharmaceuticals","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"","productType":"Small molecule","year":"2022","type":"Not Applicable","leadProduct":"Minocycline Hydrochloride","moa":"","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"Biorasi","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"","sponsorNew":"Biorasi \/ Citius Pharmaceuticals","highestDevelopmentStatusID":"10","companyTruncated":"Biorasi \/ Citius Pharmaceuticals"},{"orgOrder":0,"company":"Biorasi","sponsor":"Longeveron","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"","productType":"Cell and Gene therapy","year":"2022","type":"Not Applicable","leadProduct":"Allogeneic Bone Marrow-derived Medicinal Signaling Cells","moa":"","graph1":"Neurology","graph2":"Phase II","graph3":"Biorasi","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Biorasi \/ bioRASI","highestDevelopmentStatusID":"8","companyTruncated":"Biorasi \/ bioRASI"},{"orgOrder":0,"company":"Biorasi","sponsor":"Alzamend Neuro","pharmaFlowCategory":"D","therapeuticArea":"Neurology","country":"","productType":"Vaccine","year":"2023","type":"Partnership","leadProduct":"ALZN002","moa":"","graph1":"Neurology","graph2":"Phase I\/ Phase II","graph3":"Biorasi","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"","sponsorNew":"Biorasi \/ Biorasi","highestDevelopmentStatusID":"7","companyTruncated":"Biorasi \/ Biorasi"}]

Find Clinical Drug Pipeline Developments & Deals by Biorasi

Menu
Xls
Filters Filter
×
FILTER:
filter
Company Name
    filter

    Year

      filter

      DEALS // DEV.

        filter

        Country

          filter
          Sponsor
            filter

            Therapeutic Area

              filter

              Study Phase

                filter

                Deal Type

                  filter

                  Product Type

                    filter

                    Dosage Form

                      filter

                      Lead Product

                        filter

                        Target

                          Loading...

                          Therapeutic Area by Lead Product

                          Study Phase by Lead Product

                          Company by Lead Product

                          Top Deals by Deal Size (USD bn)

                          01

                          Compamed
                          Not Confirmed
                          Compamed
                          Not Confirmed

                          Details : ALZN002 is a proprietary active immunotherapy product. It consists of autologous DCs, which are activated WBCs taken from each individual patient that are then engineered outside of the body to attack Alzheimer’s-related amyloid-beta proteins.

                          Brand Name : ALZN002

                          Molecule Type : Vaccine

                          Upfront Cash : Undisclosed

                          January 04, 2023

                          Lead Product(s) : ALZN002

                          Therapeutic Area : Neurology

                          Highest Development Status : IND Enabling

                          Recipient : Alzamend Neuro

                          Deal Size : Undisclosed

                          Deal Type : Partnership

                          blank

                          02

                          Compamed
                          Not Confirmed
                          Compamed
                          Not Confirmed

                          Lead Product(s) : Allogeneic Bone Marrow-derived Medicinal Signaling Cells

                          Therapeutic Area : Neurology

                          Study Phase : Phase II

                          Recipient : Longeveron

                          Deal Size : Not Applicable

                          Deal Type : Not Applicable

                          Details : Lomecel-B, an allogeneic medicinal signaling cell (MSC) therapy product isolated from the bone marrow of adult donors. Longeveron is advancing Lomecel-B through clinical trials in 3 indications: Hypoplastic Left Heart Syndrome, Alzheimer’s Disease, and...

                          Brand Name : Lomecel-B

                          Molecule Type : Cell and Gene therapy

                          Upfront Cash : Not Applicable

                          November 10, 2022

                          Lead Product(s) : Allogeneic Bone Marrow-derived Medicinal Signaling Cells

                          Therapeutic Area : Neurology

                          Highest Development Status : Phase II

                          Recipient : Longeveron

                          Deal Size : Not Applicable

                          Deal Type : Not Applicable

                          blank

                          03

                          Compamed
                          Not Confirmed
                          Compamed
                          Not Confirmed

                          Details : Mino-Lok (minocycline) is an antibiotic lock solution used to treat patients with catheter-related bloodstream infections (CRBSIs) and central line associated bloodstream infections (CLABSIs).

                          Brand Name : Mino-Lok

                          Molecule Type : Small molecule

                          Upfront Cash : Not Applicable

                          May 06, 2022

                          Lead Product(s) : Minocycline Hydrochloride,EDTA acid,Ethanol

                          Therapeutic Area : Infections and Infectious Diseases

                          Highest Development Status : Phase III

                          Sponsor : Citius Pharmaceuticals

                          Deal Size : Not Applicable

                          Deal Type : Not Applicable

                          blank

                          04

                          Compamed
                          Not Confirmed
                          Compamed
                          Not Confirmed

                          Details : JadiCell (mesenchymal stem cells), was shown to be 100% effective in saving the lives of COVID-19 patients under age of 85 in a double-blind, randomized, placebo controlled clinical trial with patients in the ICU on a ventilator.

                          Brand Name : JadiCell

                          Molecule Type : Cell and Gene therapy

                          Upfront Cash : Not Applicable

                          May 02, 2022

                          Lead Product(s) : Mesenchymal Stem Cells

                          Therapeutic Area : Infections and Infectious Diseases

                          Highest Development Status : Phase III

                          Recipient : Therapeutic Solutions

                          Deal Size : Not Applicable

                          Deal Type : Not Applicable

                          blank